We are live on ! Find out more
KCM

Kalehua Capital Management Portfolio holdings

AUM $174M
This Fund
S&P 500
This Quarter Est. Return
+9.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$40.2M
Cap. Flow
+$42.1M
Cap. Flow %
29.81%
Top 10 Hldgs %
72.71%
Holding
28
New
9
Increased
1
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$16.1M
2
MANE
Veradermics Inc
MANE
+$7.35M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$6.18M
4
QURE icon
uniQure
QURE
+$5.89M
5
PEPG icon
PepGen
PEPG
+$5.62M

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$3.49M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$2.18M
3
VRCA icon
Verrica Pharmaceuticals
VRCA
+$1.96M
4
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$1.45M
5
DMAC icon
DiaMedica Therapeutics
DMAC
+$260K

Sector Composition

Rank Sector Weight
1 Healthcare 81.79%
2 Materials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
26
Allogene Therapeutics
ALLO
$743M
– –
-2,546,129
Closed -$3.49M
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.45B
– –
-267,059
Closed -$2.18M
VRCA icon
28
Verrica Pharmaceuticals
VRCA
$83.8M
– –
-235,779
Closed -$1.96M
1
2

Similar funds

PWSG
Pacific Wealth Strategies Group Santa Barbara, California $174M AUM 21.47% 1-Year Est. Return
6SA
6th Street Advisors Daphne, Alabama $174M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $174M AUM
PIA
Prakash Investment Advisors Andover, Massachusetts $174M AUM 85.35% 1-Year Est. Return
CPCP
Cedar Point Capital Partners Cedar Rapids, Iowa $174M AUM 19.71% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $174M AUM 29.38% 1-Year Est. Return
MCM
MontVue Capital Management Lynchburg, Virginia $174M AUM 24.95% 1-Year Est. Return
AIA
Accelerate Investment Advisors Aliso Viejo, California $174M AUM 23.04% 1-Year Est. Return

Kalehua Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Kalehua Capital Management held 28 positions worth $141M, up 40% from $101M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kalehua Capital Management deployed $42.1M of net new capital in Q1 2026, opening 9 new positions and adding to 1 existing holding. Its largest new stake was Gossamer Bio: 10,236,293 shares worth $3.36M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Alpha Architect 1-3 Month Box ETF, an estimated $1.45M trimmed.

  • Kalehua Capital Management's largest Q1 2026 buy was Gossamer Bio: 10,236,293 shares worth $3.36M.
  • Kalehua Capital Management added most to Inhibikase Therapeutics in Q1 2026, an estimated $3.68M increase.
  • Kalehua Capital Management's biggest Q1 2026 reduction was Alpha Architect 1-3 Month Box ETF, cutting an estimated $1.45M.
  • Kalehua Capital Management fully exited Allogene Therapeutics in Q1 2026, selling an estimated $3.49M.
  • Kalehua Capital Management's ten largest holdings make up 73% of its $141M portfolio in Q1 2026.
  • Kalehua Capital Management opened 9 new positions and closed 3 in Q1 2026.
  • Kalehua Capital Management's portfolio value rose 40% quarter-over-quarter to $141M.

Based on Kalehua Capital Management's 13F filing for Q1 2026, filed 15 May 2026.